Omega -3 Fatty Acid in Combination With Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia

NCT04006847 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

1

Enrollment

OTHER

Sponsor class

Stopped Product complaint

Conditions

Chronic Myeloid Leukemia, Chronic Phase

Interventions

DRUG: Eicosapentaenoic Acid
DRUG: Tyrosine kinase inhibitor

Sponsor

Milton S. Hershey Medical Center